Jenne Kyle 4

What Happened

• Jenne Kyle, EVP & Chief Global Product Strategy Officer at Ionis Pharmaceuticals, had 12,226 Restricted Stock Units (RSUs) vest on 2026-04-15 and the RSUs converted into 12,226 shares (reported as acquired at $0.00). Following vesting, 4,902 of those shares were sold on 2026-04-16 in an automatic sale to cover tax withholding, yielding proceeds of $368,488 at a weighted average price of $75.17. The sale prices ranged from $75.06 to $75.26.

Key Details

• Transaction dates: RSU vesting/conversion 2026-04-15; sale to cover taxes 2026-04-16; Form 4 filed 2026-04-17 (timely).
• Acquired: 12,226 shares upon RSU vesting (reported at $0.00) — see footnotes on RSU treatment.
• Sold: 4,902 shares; weighted avg price $75.17; total proceeds $368,488. Sales occurred across multiple trades at $75.06–$75.26.
• Purpose of sale: automatic sale to cover required tax withholding under the 2011 Equity Incentive Plan (footnote).
• Footnotes: RSUs represent a contingent right to one share and vest in four equal annual installments; upon vesting they are paid in shares or cash per the plan. The filer can provide a price-by-price breakdown on request.
• Shares owned after the transaction: not specified in the filing.

Context

• These were RSU vesting and an automatic tax-withholding sale (not an open-market investment decision). For derivative transactions: RSUs are not option exercises for cash gain — they are grants that converted into shares upon vesting, and a portion was sold immediately to satisfy tax obligations. This pattern is common and typically routine for executives receiving equity compensation.